Patients with high risk of abnormal new growth of tissue or may be a tumour from their bone marrow disease (known as myeloproliferative neoplasm, MPN) are often and have long been receiving treatment with antineoplastic drug to suppresses the production of blood cell precursor in the bone marrow. However, this drug (known as hydroxyurea, HU) seem causing toxicities in the skin. This is based on studied among 993 patients registered between 1980 and 2009, including 614 (61.8) who received HU from four different hematologic centers for Philadelphia chromosome-negative MPN patients. According to the study authors, Dr. Roberto Latagliata from La Sapienza University in Rome and colleagues said that their findings showed the severe and frequent of skin toxicity during HU treatment no longer categorized as ‘mild’ like it was believed for decades from … Read entire article »